Conexeu Sciences Lists 25.3 M Shares on Nasdaq, Advances 3D Breast Regeneration
Conexeu Sciences began Nasdaq trading under CNXU with 25.27 million shares outstanding and 35.24 million fully diluted, marking its entry into public markets. The preclinical biotech firm’s CXU platform supports regeneration applications like its B.R.E.A.S.T. 3D-bioprinted breast scaffold, targeting multi-billion-dollar tissue markets.
1. Nasdaq Trading Debut
On May 21, 2026, Conexeu Sciences officially commenced trading on the Nasdaq exchange under the ticker CNXU, signifying its transition from private to public status. This debut provides increased visibility and access to public capital markets to support ongoing development of its regenerative tissue platform.
2. Share Structure
The company entered trading with 25,269,996 shares issued and outstanding and 35,238,222 shares on a fully diluted basis. H.C. Wainwright & Co. served as exclusive financial advisor for the public listing, which underpins Conexeu’s plans for future fundraising.
3. Innovative Regeneration Platform
Conexeu’s proprietary CXU™ bioregenerative extracellular matrix platform underlies its B.R.E.A.S.T.™ 3D-bioprinted regenerative breast matrix, designed to function as a temporary scaffold that resorbs as native tissue remodels. The preclinical program focuses on restoring lost or damaged soft tissue with potential applications across wound care, periodontal therapy and body contouring.
4. Market Opportunity and Outlook
More than 100,000 U.S. women undergo mastectomy annually, highlighting demand for novel reconstruction options. Conexeu targets large, multibillion-dollar end markets and plans a 510(k) submission for its initial indication in early 2027, leveraging its decade-old platform and issued patents across major jurisdictions.